TNFRSF13C and diabetes mellitus: Overexpressing CD73 with agents, such as AGT-5, Aire-overexpressing DCs, BAFFR-Fc, CD4+ peptide, ICAs, IL-2 therapies, SAgAs, sCD73, RAD51 inhibitor, TLR9 inhibitor, and VD decreases diabetes development (Figure 1A).